Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study: does less invasive prostate treatment preserve quality of life?

NCT ID NCT06945172

Symptom relief Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This study will compare how men with intermediate-risk prostate cancer feel about their quality of life after either total prostate removal (surgery) or a less invasive treatment called focal HIFU (high-intensity focused ultrasound). About 100 sexually active men aged 40-75 will answer questionnaires 6, 12, and 24 months after treatment. The goal is to see which approach better preserves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this trial shows that focal HIFU leads to better quality of life than total prostatectomy, it could help men with prostate cancer choose a less invasive treatment option.
What could go wrong
This is a small, early-stage study (102 participants) that only measures quality of life, not cancer control. It may not show a clear difference, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 102 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient, male, aged between ≥ 40 and ≤ 75 years * Patient with a life expectancy \> 10 years at the time of inclusion. * Patient with a therapeutic strategy (prostatectomy or focal HIFU) defined during a PCR. * Patient with a diagnosis of localised prostate cancer at favourable intermediate risk * Patient able to tolerate general anaesthesia or type IV sedation * Patient with normal urinary continence status * Patient with satisfactory erectile function allowing penetration: * Patient with targeted biopsies and systematic biopsies * Patient affiliated to or benefiting from a social security scheme * French-speaking patients who do not object to the use of their data. Exclusion Criteria: * Patients with a contraindication to MRI * Stage T3a or b on MRI * Patient on long-term anticoagulants and unable to stop them. * Patient already included in another study * Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Favorable intermediate-risk localized prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinique La Croix du Sud

    RECRUITING

    Quint-Fonsegrives, 31130, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.